Peggy L. Porter

17.9k total citations · 5 hit papers
140 papers, 13.3k citations indexed

About

Peggy L. Porter is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Peggy L. Porter has authored 140 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Oncology, 59 papers in Cancer Research and 39 papers in Genetics. Recurrent topics in Peggy L. Porter's work include Cancer Risks and Factors (49 papers), Breast Cancer Treatment Studies (41 papers) and Global Cancer Incidence and Screening (24 papers). Peggy L. Porter is often cited by papers focused on Cancer Risks and Factors (49 papers), Breast Cancer Treatment Studies (41 papers) and Global Cancer Incidence and Screening (24 papers). Peggy L. Porter collaborates with scholars based in United States, South Africa and Norway. Peggy L. Porter's co-authors include Janet R. Daling, Kathleen E. Malone, Christopher I. Li, James M. Roberts, Eduardo Firpo, Stephen M. Schwartz, Emily White, James K. McDougall, Margaret M. Madeleine and Denise A. Galloway and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Peggy L. Porter

139 papers receiving 12.9k citations

Hit Papers

A Syndrome of Multiorgan ... 1996 2026 2006 2016 1996 1997 2012 2004 2002 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 -Deficient Mice
    1996 1.3k citations Peggy L. Porter, Eduardo Firpo et al. profile →
  2. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
    1997 791 citations Peggy L. Porter, Kathleen E. Malone et al. profile →
  3. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
    2012 621 citations Peggy L. Porter et al. profile →
  4. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer
    2004 600 citations Janet R. Daling, Peggy L. Porter et al. Cancer profile →
  5. Randomized Trial of Breast Self-Examination in Shanghai: Final Results
    2002 515 citations Peggy L. Porter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peggy L. Porter United States 60 7.5k 4.1k 3.9k 2.0k 2.0k 140 13.3k
Margaret A. Tucker United States 65 7.3k 1.0× 4.7k 1.1× 2.9k 0.7× 2.0k 1.0× 3.4k 1.7× 230 16.0k
Alisa M. Goldstein United States 57 4.9k 0.6× 6.3k 1.5× 2.6k 0.7× 1.2k 0.6× 1.8k 0.9× 253 12.7k
Stephen B. Gruber United States 58 5.5k 0.7× 3.6k 0.9× 3.6k 0.9× 1.2k 0.6× 2.2k 1.1× 231 12.4k
Xavier Matías‐Guiu Spain 64 4.2k 0.6× 6.4k 1.5× 3.5k 0.9× 1.9k 0.9× 1.3k 0.6× 435 16.1k
Russell R. Broaddus United States 69 4.9k 0.6× 5.8k 1.4× 4.4k 1.1× 1.3k 0.6× 1.7k 0.9× 286 15.1k
Andrew Berchuck United States 73 5.8k 0.8× 8.1k 2.0× 3.8k 1.0× 1.1k 0.6× 2.9k 1.5× 358 19.9k
Christian Marth Austria 61 5.3k 0.7× 5.8k 1.4× 2.8k 0.7× 1.0k 0.5× 1.6k 0.8× 411 14.0k
Frédéric Amant Belgium 66 7.2k 1.0× 3.7k 0.9× 3.2k 0.8× 2.3k 1.1× 1.5k 0.7× 554 21.9k
David G. Mutch United States 68 4.3k 0.6× 4.0k 1.0× 2.9k 0.7× 3.3k 1.7× 1.3k 0.6× 449 19.1k
Robert L. Coleman United States 72 7.7k 1.0× 7.7k 1.9× 3.5k 0.9× 2.0k 1.0× 1.6k 0.8× 690 23.3k

Countries citing papers authored by Peggy L. Porter

Since Specialization
Citations

This map shows the geographic impact of Peggy L. Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peggy L. Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peggy L. Porter more than expected).

Fields of papers citing papers by Peggy L. Porter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peggy L. Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peggy L. Porter. The network helps show where Peggy L. Porter may publish in the future.

Co-authorship network of co-authors of Peggy L. Porter

This figure shows the co-authorship network connecting the top 25 collaborators of Peggy L. Porter. A scholar is included among the top collaborators of Peggy L. Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peggy L. Porter. Peggy L. Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Christopher I., Meghan R. Flanagan, Mei‐Tzu C. Tang, Peggy L. Porter, & Kathleen E. Malone. (2021). Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma In Situ. Cancer Research. 81(10). 2799–2802. 2 indexed citations
2.
Li, Christopher I., Yuping Zhang, Marcin Cieślik, et al.. (2021). Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. Clinical Cancer Research. 27(11). 3079–3093. 10 indexed citations
3.
Balakrishnan, Ashwini, Tracy Goodpaster, Julie Randolph‐Habecker, et al.. (2016). Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clinical Cancer Research. 23(12). 3061–3071. 151 indexed citations
4.
Rodler, Eve T., Brenda F. Kurland, Melissa Griffin, et al.. (2016). Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer. Clinical Cancer Research. 22(12). 2855–2864. 69 indexed citations
5.
Chen, Lu, Christopher I. Li, Mei-Tzu C. Tang, et al.. (2016). Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women. Cancer Epidemiology Biomarkers & Prevention. 25(9). 1297–1304. 33 indexed citations
6.
Beaber, Elisabeth F., Kathleen E. Malone, Mei-Tzu C. Tang, et al.. (2014). Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women. Cancer Epidemiology Biomarkers & Prevention. 23(5). 755–764. 53 indexed citations
7.
Li, Christopher I., Elisabeth F. Beaber, Mei Tang, et al.. (2012). Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. Breast Cancer Research and Treatment. 137(2). 579–587. 101 indexed citations
8.
Amon, Lynn M., Sharon J. Pitteri, Christopher I. Li, et al.. (2012). Concordant Release of Glycolysis Proteins into the Plasma Preceding a Diagnosis of ER+ Breast Cancer. Cancer Research. 72(8). 1935–1942. 26 indexed citations
9.
Phipps, Amanda I., Diana S.M. Buist, Kathleen E. Malone, et al.. (2010). Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes & Control. 22(3). 399–405. 72 indexed citations
10.
Harigopal, Malini, William E. Barlow, Peggy L. Porter, et al.. (2010). Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome. American Journal Of Pathology. 176(4). 1639–1647. 32 indexed citations
11.
Tubbs, Raymond, William E. Barlow, G. Thomas Budd, et al.. (2009). Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status. Journal of Clinical Oncology. 27(24). 3881–3886. 53 indexed citations
12.
Daling, Janet R., Emily White, Louise A. Brinton, et al.. (2009). Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. Cancer Epidemiology Biomarkers & Prevention. 18(4). 1157–1166. 196 indexed citations
13.
Phipps, Amanda I., Kathleen E. Malone, Peggy L. Porter, Janet R. Daling, & Christopher I. Li. (2008). Reproductive and hormonal risk factors for postmenopausal luminal, HER‐2‐overexpressing, and triple‐negative breast cancer. Cancer. 113(7). 1521–1526. 104 indexed citations
14.
Chin, Suet‐Feung, Andrew E. Teschendorff, John C. Marioni, et al.. (2007). High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome biology. 8(10). R215–R215. 239 indexed citations
15.
Garrett-Engele, Carrie M., Uta Kossatz-Boehlert, Xueyan Chen, et al.. (2006). Testing the importance of p27 degradation by the SCF skp2 pathway in murine models of lung and colon cancer. Proceedings of the National Academy of Sciences. 103(38). 14009–14014. 60 indexed citations
16.
Loo, Lenora W. M., Carl C.T. Ton, Douglas I. Grove, et al.. (2006). Identification of genomic alterations differentiating lobular and ductal subtypes of breast cancer. Cancer Research. 66. 611–612. 2 indexed citations
17.
Chappuis, Pierre O., John R. Goffin, Nora Wong, et al.. (2005). Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Annals of Oncology. 16(5). 735–742. 39 indexed citations
18.
Loo, Lenora W. M., Douglas I. Grove, Eleanor Williams, et al.. (2004). Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes. Cancer Research. 64(23). 8541–8549. 173 indexed citations
19.
Sparks, Rachel, Cornelia M. Ulrich, Jeannette Bigler, et al.. (2004). UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Research. 6(5). R488–98. 64 indexed citations
20.
Moe, Roger E., Kris S. Moe, Peggy L. Porter, et al.. (1991). Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers. The American Journal of Surgery. 161(5). 580–583. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margaret A. Tucker Breakdown of academic impact, for papers by Alisa M. Goldstein Breakdown of academic impact, for papers by Stephen B. Gruber Breakdown of academic impact, for papers by Xavier Matías‐Guiu Breakdown of academic impact, for papers by Russell R. Broaddus Breakdown of academic impact, for papers by Andrew Berchuck Breakdown of academic impact, for papers by Christian Marth Breakdown of academic impact, for papers by Frédéric Amant Breakdown of academic impact, for papers by David G. Mutch Breakdown of academic impact, for papers by Robert L. Coleman
Rankless by CCL
2026